



Amal Therapeutics announces the signature of an Exclusive Patent License Agreement for the use of a peptide with immunomodulation properties

Geneva, Switzerland, October 27, 2015 – Amal Therapeutics SA ("Amal"), a biotechnology company active in cancer immunotherapy announced today the signature of an exclusive patent license agreement with the University of Minnesota for the use of a novel peptide with potent immunostimulatory properties.

This novel peptide was discovered by the University of Minnesota's Dr. John Ohlfest and Dr. Mike Olin seeking to enhance the effects of immunotherapy cancer vaccines. It was shown to have a unique mechanism of action, which led to significant activity over other adjuvants in pre-clinical testing.

"The signature of this exclusive license agreement is an important milestone in the Amal development process. It consolidates our IP position and gives Amal the freedom to operate to further develop its Kisima technology platform" said Madiha Derouazi, Amal Therapeutics CEO.

About Amal Therapeutics SA

Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses Kisima, its proprietary technology platform, to develop and progress therapeutic vaccines in oncology. www.amaltherapeutics.com, contact@amaltherapeutics.com

About the University of Minnesota

Founded in 1851, the University of Minnesota is ranked among the nation's top public research universities. As a land-grant institution, the U of M is committed to engaging Minnesota, national and global communities to advance interdisciplinary knowledge; enhance students' academic, civic, career, social and personal development; and apply intellectual and human capital to serve the public good